Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Franziska Wachter, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
2022 - 2024
ASH Scholar Award
2022 - 2024
2022 OFD/BTREC/CTREC Award
2022 - 2024
ICCTR/Harvard Catalyst
2020 - 2021
Boston Combined Residency Program Fellow Teaching Honor Roll for the 2020-2021 academic year
2019 - 2020
Boston Combined Residency Program Faculty Teaching Honor Roll for the 2019-2020 academic year
2015 - 2016
Feodor Lynen Postdoctoral Research Fellowship
2009 - 2013
Konrad Adenauer Foundation Fellowship

Mentoring
Available: 01/10/22, Expires: 06/01/22

Nearly half of all children diagnosed with myeloid malignancies will not be cured, suggesting that novel therapeutic strategies are needed. The prognostic impact of complete remission (CR) and measurable residual disease (MRD) negativity for pediatric patients with myeloid malignancies undergoing SCT (stem cell transplant) is not well established. Recent adult consensus guidelines have supported the use of a new response criterion: CR without MRD (CRMRD) which is now considered the optimal response in adult acute myeloid leukemia (AML) and is the gold standard prior to consolidation with SCT. The data supporting this recommendation are based on studies in the frontline adult AML; limited data exists regarding the prognostic impact of MRD pre SCT in the setting of relapsed myeloid malignancies or myelodysplastic syndrome). Moreover, its applicability to pediatric patients with relapsed/refractory AML or MDS is largely unknown. This is a retrospective study to characterize the impact of pre SCT MRD on risk of relapse after SCT for pediatric patients with myeloid malignancies. We will look at all patients who were evaluated for transplant for AML in our program from 1/2010 through 12/2021 and will gather information regarding their pre-SCT disease status and post-SCT outcomes. Varied methodologies (flow cytometry, FISH, genomic sequencing) were used to measure MRD and we will assess the impact of pre transplant disease burden is on post SCT outcomes. We will also analyze other factors that may impact risk for relapse including, but not limited to, donor haplotype and incidence and severity of graft versus host disease. We anticipate our study will inform the threshold of disease response needed for long term cure in the context of relapsed AML and MDS and may serve as a platform for development of interventional therapeutic studies designed to abrogate pre SCT MRD and minimize post SCT MRD emergence. Potential role of the student: Chart review, data collection for the relapsed AML population. IRB is completed. The data collection for the MDS population was already completed and the analysis is ongoing by the statistical team - the student could also gain insight in this piece. Plan for publication of this project.


Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Aziz-Bose R, Wachter F, Chiarle R, Lindeman NI, Kim AS, Degar B, Davies K, Pikman Y. Rapid next generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Adv. 2022 Jan 28. PMID: 35090166.
    Citations:    Fields:    
  2. Wachter F, Al-Ibraheemi A, Trissal MC, Hollowell M, DuBois SG, Collins NB, Church AJ, Janeway KA. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. Pediatrics. 2021 12 01; 148(6). PMID: 34814185.
    Citations:    Fields:    Translation:Humans
  3. Wachter F, Archer NM. Autoimmune hemolytic anemia complicated by parvovirus infection. Blood. 2021 02 25; 137(8):1130. PMID: 33630052.
    Citations: 1     Fields:    Translation:HumansCells
  4. Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Res. 2019 05 01; 79(9):2404-2414. PMID: 30755442.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  5. Pease-Raissi SE, Pazyra-Murphy MF, Li Y, Wachter F, Fukuda Y, Fenstermacher SJ, Barclay LA, Bird GH, Walensky LD, Segal RA. Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration. Neuron. 2017 Oct 11; 96(2):373-386.e6. PMID: 29024661.
    Citations: 35     Fields:    Translation:AnimalsCells
  6. Pritz JR, Wachter F, Lee S, Luccarelli J, Wales TE, Cohen DT, Coote P, Heffron GJ, Engen JR, Massefski W, Walensky LD. Allosteric sensitization of proapoptotic BAX. Nat Chem Biol. 2017 Sep; 13(9):961-967. PMID: 28692068.
    Citations: 17     Fields:    Translation:HumansCells
  7. Wachter F, Morgan AM, Godes M, Mourtada R, Bird GH, Walensky LD. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene. 2017 04; 36(15):2184-2190. PMID: 27721413.
    Citations: 14     Fields:    Translation:HumansCells
  8. Edwards AL, Wachter F, Lammert M, Huhn AJ, Luccarelli J, Bird GH, Walensky LD. Cellular Uptake and Ultrastructural Localization Underlie the Pro-apoptotic Activity of a Hydrocarbon-stapled BIM BH3 Peptide. ACS Chem Biol. 2015 Sep 18; 10(9):2149-57. PMID: 26151238.
    Citations: 17     Fields:    Translation:AnimalsCells
  9. Barclay LA, Wales TE, Garner TP, Wachter F, Lee S, Guerra RM, Stewart ML, Braun CR, Bird GH, Gavathiotis E, Engen JR, Walensky LD. Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism. Mol Cell. 2015 Mar 05; 57(5):873-886. PMID: 25684204.
    Citations: 65     Fields:    Translation:HumansCells
  10. Ehrhardt H, Pfeiffer S, Schrembs D, Wachter F, Grunert M, Jeremias I. Activation of DNA damage response by antitumor therapy counteracts the activity of vinca alkaloids. Anticancer Res. 2013 Dec; 33(12):5273-87. PMID: 24324060.
    Citations: 2     Fields:    Translation:HumansCells
  11. Ehrhardt H, Wachter F, Grunert M, Jeremias I. Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis. Cell Death Dis. 2013 Jun 06; 4:e661. PMID: 23744361.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  12. Wachter F, Grunert M, Blaj C, Weinstock DM, Jeremias I, Ehrhardt H. Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling. Cell Commun Signal. 2013 Apr 17; 11(1):27. PMID: 23594441.
    Citations: 2     Fields:    
  13. Ehrhardt H, Pannert L, Pfeiffer S, Wachter F, Amtmann E, Jeremias I. Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies. Br J Pharmacol. 2013 Apr; 168(7):1558-69. PMID: 23186127.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  14. Ehrhardt H, Höfig I, Wachter F, Obexer P, Fulda S, Terziyska N, Jeremias I. NOXA as critical mediator for drug combinations in polychemotherapy. Cell Death Dis. 2012 Jun 21; 3:e327. PMID: 22717582.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  15. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I. Important role of caspase-8 for chemosensitivity of ALL cells. Clin Cancer Res. 2011 Dec 15; 17(24):7605-13. PMID: 22010212.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  16. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U, Nathrath M, Jeremias I. Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood. 2011 Dec 01; 118(23):6123-31. PMID: 21926351.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Wachter's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (122)
Explore
_
Co-Authors (26)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.